Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ad5-yCD/mutTKSR39rep-hIL12 in locally recurrent prostate cancer
NCT02555397Phase 1Completed
- Sponsor
- Henry Ford Health
- Start
- Aug 2015
- Primary completion
- Jun 2019
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of Ad5-yCD/mutTKSR39rep-hIL12 in prostate cancer (PCa), sponsored by Henry Ford Health. Primary endpoint: Dose-dependent Toxicity at 30 days. Started Aug 2015; status: completed.
02
Drugs
Ad5-yCD/mutTKSR39rep-hIL12
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT02555397.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02555397.